This product is a box of 10 vials.
What Is Gonadorelin ?
Gonadorelin is a gonadotropin releasing hormone agonist that has shown benefit in treating infertility and hypogonadism. Recent research suggests that gonadorelin may help slow the growth of breast and prostate cancer. Studies also show promise in treating Alzheimer's disease.
Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
Molecular Formula: C55H75N17O13
Molecular Weight: 1182.311 g/mol
PubChem CID: 638793
CAS Number: 9034-40-6
Synonyms: Growth Hormone Releasing Factor, Somatocrinin, Somatoliberin
Breast Cancer Prevention
Research suggests that higher lifetime exposure to estrogen may increase a woman's chance of developing breast cancer. Women who start their period at a younger age, go through menopause later, take estrogen-containing birth control, or have hormone replacement therapy during menopause all have a higher risk of breast cancer. Thankfully, in the case of birth control, the risk decreases when the pills are stopped and eventually returns to normal. Of course, birth control is a double-edged sword because even though its use increases breast cancer risk, it decreases ovarian cancer risk.
Some breast cancer cells need estrogen to grow, and reducing estrogen production or blocking estrogen receptors has long been a way to treat certain forms of breast cancer. Research into gonadorelin shows that it can suppress ovarian production of estrogen, which may help prevent breast cancer. This idea is based on the fact that some women, due to genetic and environmental factors, are at higher risk of breast cancer after menopause. Using gonadorelin in this case is safe and cost-effective, making it an attractive way to reduce cancer burden.
The benefits of gonadorelin do not stop at breast cancer prevention. Research indicates that add-on therapy with anti-estrogens reduces disease progression by as much as 50% in cases where cancer responds to estrogen. Unfortunately, currently available treatments are limited because cancer cells often develop resistance over time. This resistance usually comes from increased estrogen receptor expression, making it impossible to block every estrogen receptor without severe side effects. Gonadorelin could avoid this problem by reducing estrogen expression from the start. This would not only directly slow growth of estrogen-sensitive cancer but also boost the effectiveness of receptor-blocking medications and extend their useful lifespan.
Research in postmenopausal women with high androgen levels (too much estrogen) has shown that long-term GnRH treatment reduces overall estrogen levels and thus the risk of breast cancer. It does so without serious side effects and offers an alternative to the current therapy, which is surgical removal of the ovaries.
Prostate Cancer
Dementia Risk
Further Research
Research indicates that sex hormones, particularly luteinizing hormone (LH), act on the brain in ways beyond sexual differences or reproduction. In fact, the rise in LH that comes with menopause has been linked to a higher incidence of Alzheimer’s disease and reduced memory performance in both humans and animals. Careful research in rats further shows that LH acts directly on the hippocampus, the main memory center in the brain. Rats given LH show decreased memory performance and hippocampus dysfunction, a deficit reversed by an LH-blocking drug.
Further research on LH has shown that higher levels of the hormone are linked to increased brain pathology. In particular, LH promotes the development of plaques associated with Alzheimer’s. It makes sense then that reducing LH levels could help slow Alzheimer’s progression. This has been shown, at least partly, in mouse models where removing the LH receptor in the brain improves amyloid pathology and helps preserve the health of cells like astrocytes, which support and protect neurons.
As it turns out, testosterone benefits brain health and helps preserve cognitive function. Thus, simply blocking the entire hypothalamic-pituitary-gonadal axis is not necessarily an effective way to treat Alzheimer’s. That is why scientists have tested gonadorelin versions to see if selective interference in LH production is possible and beneficial. This research, while ongoing, has led to studies showing that leuprolide (a common medication for uterine fibroids and a GnRH receptor agonist) effectively decreases Alzheimer’s risk compared to other gonadorelin versions. Ongoing research can help define why this is, but it is important to note that men using highly effective CAB treatment against prostate cancer need not choose between cancer and Alzheimer’s. Leuprolide can offset CAB's risks regarding Alzheimer’s. In particular, leuprolide's ability to lower serum gonadotrophin levels (LH especially) is generally enough to offset reduced testosterone effects.
New research seeks to understand how gonadorelin and its related compounds affect APOE and MS4A6A expression in Alzheimer’s. Both gene sites are linked to late-onset Alzheimer’s, but research suggests they need to work together to cause serious problems and that interfering with one or the other is enough to short-circuit the pathway to disease. Gonadorelin affects this tandem interaction, but it is not clear how or why. Right now, researchers are working to see how gene interactions in Alzheimer’s can be interrupted to treat and prevent the condition. Gonadorelin is an important peptide in that research.
Despite what popular media might suggest, prostate cancer is actually the most hormone-sensitive of all cancers. This may seem like a problem, but it actually offers a chance for treatment. In short, by cutting off the supply of testosterone and its related hormones to prostate cancer, it is possible to greatly slow growth and even stop it. The challenge is to cut off all hormone flow. This first led to surgical removal of the testicles in men with aggressive prostate cancer, a procedure quickly replaced by gonadorelin when it was found to be just as effective and potentially reversible.
The use of GnRH in men with prostate cancer began as far back as 1979 and was called medical castration. This treatment eventually led to an interesting finding: some androgens are made locally in the prostate through a process called intracrinology. This means GnRH blockade is only partly effective in treating prostate cancer. With gonadorelin's help, scientists developed two new drugs accepted by the FDA for treating castration-resistant prostate cancer (CRPC). These drugs are very important and offer a new defense against prostate cancer progression and spread. They may even find use as preventives in older men.
The use of both gonadorelin and newer, targeted drugs in prostate cancer treatment is called combined androgen blockage (CAB). When combined with effective screening and early detection, CAB is one of the few therapies in cancer treatment to offer a cure—not just remission, but a cure. When used well and with early detection, CAB makes it possible to cure 99% of all prostate cancer.
Gonadorelin is hardly a new peptide in treating human and mammalian disease, but researchers are constantly uncovering new ways GnRH and GnRH versions work in normal body functions and disease development. The discovery that gonadorelin can play a role in treating prostate cancer was a breakthrough that has allowed doctors to develop a cure so effective that fully 99% of people with prostate cancer can be cured if caught early enough. It looks like similar breakthroughs are on the horizon with studies showing how gonadorelin and its downstream hormones affect Alzheimer's disease risk.
Curious about Gonadorelin?
Join our Facebook group to engage directly with thousands of others who use this product, and follow our Facebook/IG pages for hot updates and product announcements!
